Literature DB >> 14561740

A chromatin immunoprecipitation screen reveals protein kinase Cbeta as a direct RUNX1 target gene.

Bruce A Hug1, Nazia Ahmed, Jonathan A Robbins, Mitchell A Lazar.   

Abstract

RUNX1 (also known as AML1) is a DNA-binding transcription factor that functions as a tumor suppressor and developmental determinant in hematopoietic cells. Target promoters have been identified primarily through the use of differential expression strategies and candidate gene approaches but not biochemical screens. Using a chromatin immunoprecipitation screen, we identified protein kinase Cbeta as a direct RUNX1 target gene and demonstrate that endogenous RUNX1 binds the chromatinized protein kinase Cbeta promoter of U937 cells. A phylogenetically conserved RUNX1-binding site within the PKCbeta promoter binds RUNX1 in electrophoretic mobility shift analyses and confers RUNX1 responsiveness on a heterologous promoter. Changes in RUNX1 activity affect endogenous protein kinase Cbeta expression, and a dominant-negative form of RUNX1 protects U937 cells from apoptotic stimuli previously shown to be dependent on protein kinase Cbeta. This protection can be reversed by the ectopic expression of protein kinase Cbeta. Together these findings demonstrate that protein kinase Cbeta is a direct, downstream target of RUNX1 and links RUNX1 to a myeloid apoptotic pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14561740     DOI: 10.1074/jbc.M309524200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients.

Authors:  Leilei Chen; Tim Hon Man Chan; Yun-Fei Yuan; Liang Hu; Jun Huang; Stephanie Ma; Jian Wang; Sui-Sui Dong; Kwan Ho Tang; Dan Xie; Yan Li; Xin-Yuan Guan
Journal:  J Clin Invest       Date:  2010-03-24       Impact factor: 14.808

2.  Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency.

Authors:  Gauthami Jalagadugula; Guangfen Mao; Gurpreet Kaur; Lawrence E Goldfinger; Danny N Dhanasekaran; A Koneti Rao
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

Review 3.  The current state of chromatin immunoprecipitation.

Authors:  Philippe Collas
Journal:  Mol Biotechnol       Date:  2010-05       Impact factor: 2.695

4.  An Elk transcription factor is required for Runx-dependent survival signaling in the sea urchin embryo.

Authors:  Francesca Rizzo; James A Coffman; Maria Ina Arnone
Journal:  Dev Biol       Date:  2016-05-24       Impact factor: 3.582

5.  Chromatin immunoprecipitation assay as a tool for analyzing transcription factor activity.

Authors:  Padmaja Gade; Dhan V Kalvakolanu
Journal:  Methods Mol Biol       Date:  2012

6.  The roles of RUNX3 in cervical cancer cells in vitro.

Authors:  Zhen Li; Pan Fan; Min Deng; Chao Zeng
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

7.  Platelet protein kinase C-theta deficiency with human RUNX1 mutation: PRKCQ is a transcriptional target of RUNX1.

Authors:  Gauthami Jalagadugula; Guangfen Mao; Gurpreet Kaur; Danny N Dhanasekaran; A Koneti Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-20       Impact factor: 8.311

8.  Fine mapping of a region on chromosome 21q21.11-q22.3 showing linkage to type 1 diabetes.

Authors:  R Bergholdt; J Nerup; F Pociot
Journal:  J Med Genet       Date:  2005-01       Impact factor: 6.318

9.  The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO.

Authors:  Luke F Peterson; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

10.  Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array- and sequencing-based technologies.

Authors:  Ghia M Euskirchen; Joel S Rozowsky; Chia-Lin Wei; Wah Heng Lee; Zhengdong D Zhang; Stephen Hartman; Olof Emanuelsson; Viktor Stolc; Sherman Weissman; Mark B Gerstein; Yijun Ruan; Michael Snyder
Journal:  Genome Res       Date:  2007-06       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.